Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

Z. Orfi; F. Waczek; F. Baska; I. Szabadkai; R. Torka; J. Hartmann; L. Orfi; A. Ullrich

doi:10.1038/srep44073

journal article Open Access Mar 08, 2017

Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

Z. Orfi F. Waczek F. Baska I. Szabadkai R. Torka J. Hartmann L. Orfi A. Ullrich

Scientific Reports Vol. 7 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/srep44073

Abstract

AbstractAccording to clinical data, some tyrosine kinase inhibitors (TKIs) possess antidiabetic effects. Several proposed mechanisms were assigned to them, however their mode of action is not clear. Our hypothesis was that they directly stimulate insulin release in beta cells. In our screening approach we demonstrated that some commercially available TKIs and many novel synthesized analogues were able to induce insulin secretion in RIN-5AH beta cells. Our aim was to find efficient, more selective and less toxic compounds. Out of several hits, we chose members from a compound family with quinoline core structure for further investigation. Here we present the studies done with these novel compounds and reveal structure activity relationships and mechanism of action. One of the most potent compounds (compound 9) lost its affinity to kinases, but efficiently increased calcium influx. In the presence of calcium channel inhibitors, the insulinotropic effect was attenuated or completely abrogated. While the quinoline TKI, bosutinib substantially inhibited tyrosine phosphorylation, compound9had no such effect. Molecular docking studies further supported our data. We confirmed that some TKIs possess antidiabetic effects, moreover, we present a novel compound family developed from the TKI, bosutinib and optimized for the modulation of insulin secretion.

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

Chen, J. et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert review of anticancer therapy 13, 737–743, doi: 10.1586/era.13.45 (2013). 10.1586/era.13.45

[2]

Fountas, A. et al. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens, Greece), doi: 10.14310/horm.2002.1560 (2014). 10.14310/horm.2002.1560

[3]

Mukai, E. et al. Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats. Diabetes research and clinical practice 106, 303–311, doi: 10.1016/j.diabres.2014.08.023 (2014). 10.1016/j.diabres.2014.08.023

[4]

Szalek, E. et al. The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacological reports: PR 66, 892–896, doi: 10.1016/j.pharep.2014.05.011 (2014). 10.1016/j.pharep.2014.05.011

[5]

Agostino, N. M. et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners 17, 197–202, doi: 10.1177/1078155210378913 (2011). 10.1177/1078155210378913

[6]

Prada, P. O. & Saad, M. J. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes. Expert opinion on investigational drugs 22, 751–763, doi: 10.1517/13543784.2013.802768 (2013). 10.1517/13543784.2013.802768

[7]

Fountas, A., Diamantopoulos, L.-N. & Tsatsoulis, A. Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm? Trends in Endocrinology & Metabolism 26, 643–656, doi: 10.1016/j.tem.2015.09.003 (2015). 10.1016/j.tem.2015.09.003

[8]

Malek, R. & Davis, S. N. Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. Expert opinion on investigational drugs, 1–10, doi: 10.1517/13543784.2016.1142531 (2016). 10.1517/13543784.2016.1142531

[9]

Xia, C. Q. et al. C-Abl inhibitor imatinib enhances insulin production by beta cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One 9, e97694, doi: 10.1371/journal.pone.0097694 (2014). 10.1371/journal.pone.0097694

[10]

Hagerkvist, R., Sandler, S., Mokhtari, D. & Welsh, N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. Faseb j 21, 618–628, doi: 10.1096/fj.06-6910com (2007). 10.1096/fj.06-6910com

[11]

Jain, R. et al. Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia 56, 1350–1355, doi: 10.1007/s00125-013-2877-1 (2013). 10.1007/s00125-013-2877-1

[12]

Comprehensive analysis of kinase inhibitor selectivity

Mindy I Davis, Jeremy P Hunt, Sanna Herrgard et al.

Nature Biotechnology 2011 10.1038/nbt.1990

[13]

Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotech 29, 1039–1045, doi: 10.1038/nbt.2017 (2011). 10.1038/nbt.2017

[14]

Levinson, N. M. & Boxer, S. G. Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain. PLoS ONE 7, e29828, doi: 10.1371/journal.pone.0029828 (2012). 10.1371/journal.pone.0029828

[15]

Wollheim, C. B., Blondel, B., Trueheart, P. A., Renold, A. E. & Sharp, G. W. Calcium-induced insulin release in monolayer culture of the endocrine pancreas. Studies with ionophore A23187. J Biol Chem 250, 1354–1360, Retrieved from: https://www.jbc.org/content/250/4/1354.long (1975). 10.1016/s0021-9258(19)41821-8

[16]

Nishida, A. et al. Inhibition of ATP-sensitive K+ channels and L-type Ca2+ channels by amiodarone elicits contradictory effect on insulin secretion in MIN6 cells. Journal of pharmacological sciences 116, 73–80, doi: 10.1254/jphs.10294FP (2011). 10.1254/jphs.10294fp

[17]

Ponce-Balbuena, D. et al. Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2/SUR2A channels. Mol Pharmacol 82, 803–813, doi: 10.1124/mol.112.079152 (2012). 10.1124/mol.112.079152

[18]

Gribble, F. M., Davis, T. M., Higham, C. E., Clark, A. & Ashcroft, F. M. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol 131, 756–760, doi: 10.1038/sj.bjp.0703638 (2000). 10.1038/sj.bjp.0703638

[19]

Bito, M. et al. The Mechanisms of Insulin Secretion and Calcium Signaling in Pancreatic β-Cells Exposed to Fluoroquinolones. Biological and Pharmaceutical Bulletin 36, 31–35, doi: 10.1248/bpb.b12-00425 (2013). 10.1248/bpb.b12-00425

[20]

Gilon, P., Chae, H.-Y., Rutter, G. A. & Ravier, M. A. Calcium signaling in pancreatic β-cells in health and in Type 2 diabetes. Cell Calcium 56, 340–361, doi: 10.1016/j.ceca.2014.09.001 (2014). 10.1016/j.ceca.2014.09.001

[21]

Yang, S.-N. & Berggren, P.-O. The Role of Voltage-Gated Calcium Channels in Pancreatic β-Cell Physiology and Pathophysiology. Endocrine reviews 27, 621–676, doi: 10.1210/er.2005-0888 (2006). 10.1210/er.2005-0888

[22]

Neher, E. & Marty, A. Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. Proc Natl Acad Sci USA 79, 6712–6716, doi: 10.1073/pnas.79.21.6712 (1982). 10.1073/pnas.79.21.6712

[23]

Wauson, E. M., Guerra, M. L., Barylko, B., Albanesi, J. P. & Cobb, M. H. Off-Target Effects of MEK Inhibitors. Biochemistry 52, 5164–5166, doi: 10.1021/bi4007644 (2013). 10.1021/bi4007644

[24]

Pellicena, P. & Schulman, H. CaMKII inhibitors: from research tools to therapeutic agents. Frontiers in Pharmacology 5, 21, doi: 10.3389/fphar.2014.00021 (2014). 10.3389/fphar.2014.00021

[25]

Dadi, P. K. et al. Inhibition of Pancreatic β-Cell Ca2+/Calmodulin-dependent Protein Kinase II Reduces Glucose-stimulated Calcium Influx and Insulin Secretion, Impairing Glucose Tolerance. Journal of Biological Chemistry 289, 12435–12445, doi: 10.1074/jbc.M114.562587 (2014). 10.1074/jbc.m114.562587

[26]

Yao, X.-g. et al. BBT improves glucose homeostasis by ameliorating β-cell dysfunction in type 2 diabetic mice. J. Endocrinol. 224, 327–341, doi: 10.1530/joe-14-0721 (2015). 10.1530/joe-14-0721

[27]

Easom, R. A., Filler, N. R., Ings, E. M., Tarpley, J. & Landt, M. Correlation of the activation of Ca2+/calmodulin-dependent protein kinase II with the initiation of insulin secretion from perifused pancreatic islets. Endocrinology 138, 2359–2364, doi: 10.1210/endo.138.6.5179 (1997). 10.1210/endo.138.6.5179

[28]

Selway, J. L., Moore, C. E., Mistry, R., John Challiss, R. A. & Herbert, T. P. Molecular mechanisms of muscarinic acetylcholine receptor-stimulated increase in cytosolic free Ca(2+) concentration and ERK1/2 activation in the MIN6 pancreatic beta-cell line. Acta diabetologica 49, 277–289, doi: 10.1007/s00592-011-0314-9 (2012). 10.1007/s00592-011-0314-9

[29]

Wijesekara, N. et al. Adiponectin-induced ERK and Akt Phosphorylation Protects against Pancreatic Beta Cell Apoptosis and Increases Insulin Gene Expression and Secretion. Journal of Biological Chemistry 285, 33623–33631, doi: 10.1074/jbc.M109.085084 (2010). 10.1074/jbc.m109.085084

[30]

Youl, E. et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic β-cells against oxidative damage via the ERK1/2 pathway. British Journal of Pharmacology 161, 799–814, doi: 10.1111/j.1476-5381.2010.00910.x (2010). 10.1111/j.1476-5381.2010.00910.x

[31]

Wang, Q., Heimberg, H., Pipeleers, D. & Ling, Z. Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways. Diabetologia 51, 1202–1212, doi: 10.1007/s00125-008-1026-8 (2008). 10.1007/s00125-008-1026-8

[32]

Fred, R. G., Boddeti, S. K., Lundberg, M. & Welsh, N. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. Clinical science (London, England: 1979) 128, 17–28, doi: 10.1042/cs20130560 (2015). 10.1042/cs20130560

[33]

Daouti, S. et al. Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research 69, 1924–1932, doi: 10.1158/0008-5472.can-08-2627 (2009). 10.1158/0008-5472.can-08-2627

[34]

Bae, D. & Ceryak, S. Raf-independent, PP2A-dependent MEK Activation in Response to ERK Silencing. Biochemical and biophysical research communications 385, 523–527, doi: 10.1016/j.bbrc.2009.05.082 (2009). 10.1016/j.bbrc.2009.05.082

[35]

Arnette, D. et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem 278, 32517–32525, doi: 10.1074/jbc.M301174200 (2003). 10.1074/jbc.m301174200

[36]

Blandino-Rosano, M., Perez-Arana, G., Mellado-Gil, J. M., Segundo, C. & Aguilar-Diosdado, M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. Journal of molecular endocrinology 41, 35–44, doi: 10.1677/jme-07-0154 (2008). 10.1677/jme-07-0154

[37]

Eishingdrelo, H. & Kongsamut, S. Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery. Current Chemical Genomics and Translational Medicine 7, 9–15, doi: 10.2174/2213988501307010009 (2013). 10.2174/2213988501307010009

[38]

Maechler, P., Jornot, L. & Wollheim, C. B. Hydrogen Peroxide Alters Mitochondrial Activation and Insulin Secretion in Pancreatic Beta Cells. Journal of Biological Chemistry 274, 27905–27913, doi: 10.1074/jbc.274.39.27905 (1999). 10.1074/jbc.274.39.27905

[39]

Hu, S. et al. Pancreatic β-Cell K ATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide. Journal of Pharmacology and Experimental Therapeutics 293, 444–452, Retrieved from: https://jpet.aspetjournals.org/content/293/2/444.long (2000). 10.1016/s0022-3565(24)39254-7

[40]

Mattingly, R. R. et al. The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines. Journal of Pharmacology and Experimental Therapeutics 316, 456–465, doi: 10.1124/jpet.105.091454 (2006). 10.1124/jpet.105.091454

Metrics

7

Citations

40

References

Details

Published: Mar 08, 2017
Vol/Issue: 7(1)
License: View

Authors

Cite This Article

Z. Orfi, F. Waczek, F. Baska, et al. (2017). Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue. Scientific Reports, 7(1). https://doi.org/10.1038/srep44073

Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

You May Also Like